Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market| Coherent Market Insights - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market| Coherent Market Insights

Description:

According to Coherent Market Insights,the global human immunoglobulin (pH4) for intravenous injection (COVID-19) market is estimated to lead the market during forecast period with market valuation of 17,152 US$ Mn in 2020. – PowerPoint PPT presentation

Number of Views:14
Date added: 28 July 2020
Slides: 15
Provided by: shrutiCMI
Category: Other

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market| Coherent Market Insights


1
  • Coherent Market Insights
  • Market Research and Business Consulting Services
  • https//www.coherentmarketinsights.com/
  • COVID-19 Impact Tracker

2
HUMAN IMMUNOGLOBULIN (PH4) FOR INTRAVENOUS
INJECTION MARKET ANALYSIS
  • Human Immunoglobulin (pH4) for Intravenous
    injection (COVID-19) Market,By Type (IgG, IgA,
    and IgM), By Disease Indication (COVID-19,Primary
    Immunodeficiency Disease,Immune-mediated
    Thrombocytopenia, Kawasaki Disease,B Chronic
    lymphocytic Leukemia(B-CLL),and Others),By
    Distribution Channel (Hospital Pharmacies, Retail
    Pharmacies, and Online Pharmacies) and by Region
    (North America, Latin America, Europe, Asia
    Pacific, Middle East, and Africa) - Size,
    Share,Outlook, and Opportunity Analysis, 2020 -
    2027

3
  • The global human immunoglobulin (pH4) for
  • intravenous injection (COVID-19) market is
    estimated to be valued at US 43,205.84 million
    in 2020 and is expected to exhibit a CAGR of
    12.7 during the forecast period (2020-2027).
  • Drivers
  • Human immunoglobulin is a sterile solution made
    from human plasma. Diseases such as primary
    immunodeficiency are treated by administering
    human immunoglobulin through intravenous
    injection (IGIV). Human immunoglobulin also helps
    in increasing the platelets (blood clotting
    cells) in people with immune thrombocytopenic
    purpura and prevents infections in people with
    B-cell chronic lymphocytic leukemia. Patients of
    Kawasaki syndrome are administered human
    immunoglobulin to prevent aneurysm caused due to
    weakening of the main artery in the heart.

4
  • Furthermore, intravenous human immunoglobulin
    (pH4) is being extensively researched in order to
    develop a treatment of COVID-19. This is likely
    to drive demand of human immunoglobulin (pH4) for
    intravenous injection and boost the growth of the
    global human immunoglobulin (ph4) for intravenous
    injection (COVID-19) market during the forecast
    period.

5
Figure 1.Global Human Immunoglobulin (ph4) for
Intravenous Injection (COVID-19) Market Value
(US Mn), by Region, 2020
6
Impact of Coronavirus (Covid-19) Pandemic
  • The increasing incidence of disease outbreaks is
    escalating demand for advanced diagnostic
    measures, which is expected to boost growth of
    the human immunoglobulin (pH4) for Intravenous
    Injection (COVID-19) market. For instance, the
    coronavirus disease (COVID-19) pandemic is the
    most recent outbreak which was first reported on
    December 31, 2019 in Wuhan, China. The World
    Health Organization declared coronavirus disease
    (COVID-19) as a pandemic on March 11, 2020.
    According to the World Health Organization (WHO),
    around 1,991,562 cases of the coronavirus disease
    (COVID-19) were reported on April 16, 2020 across
    the globe.

7
  • Approvals of intravenous human immunoglobulin
    products by regulatory authorities are expected
    to drive the growth of the human immunoglobulin
    (pH4) for intravenous injection (COVID-19) market
    during the forecast period. For instance, in
    September 2017, CSL Behring received the U.S.
    Food and Drug Administration (FDA) approval for
    Privigen, a human immune globulin intravenous
    liquid, indicated for the treatment of adults
    with chronic inflammatory demyelinating
    polyneuropathy (CIDP) to improve neuromuscular
    disability.

8
Market Restraint
  • Side effects such as headache, cough, fatigue,
    infusion site reaction, nausea, urticaria,
    sinusitis, blood pressure increased, diarrhea,
    dizziness, and lethargy that are associated with
    human immunoglobulin (pH4) for intravenous
    injection are expected to hinder the market
    growth. For instance, on July 2017, Octapharma
    USA Inc. issued voluntary market withdrawal of
    one lot of Octagam, a human immune globulin
    intravenous liquid, as a result of increased
    hypersensitivity events such as urticaria,
    wheezing and anaphylactoid-type responses.

9
Figure 2.Global Human Immunoglobulin (ph4) for
Intravenous Injection(COVID-19) Market Value
Share (),by Disease Indication,2020
10
Competitive Section
  • Major players operating in the global human
    immunoglobulin (pH4) for intravenous injection
    (COVID-19) market are Takeda Pharmaceutical
    Company Limited, Baxter International Inc., CSL
    Behring, Bayer AG, Grifols, S.A., Octapharma AG,
    Shanghai RAAS Blood Products Co., Ltd., Hualan
    Biological Engineering Inc, China Biologic
    Products, Inc., Sichuan Yuanda Shuyang
    Pharmaceutical Co., Ltd., Boya Bio-Pharmaceutical
    Group Co., Ltd., ADMA Biologics, Inc., and
    Sinopharm Group Co., Ltd.

11
  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Reference
  • https//www.coherentmarketinsights.com/market-insi
    ght/human-immunoglobulin-ph4-for-intravenous-injec
    tion-market-3790

12
About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions.
  • What we provide
  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

13
Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt.Ltd.
  • Address 1001 4th Ave, 3200 Seattle, WA 98154,
    U.S.
  • Phone 1-206-701-6702
  • Email sales_at_coherentmarketinsights.com

14
  • Thank You!
  • Kindly follow CMI Social Media
    Profiles for the latest company updates
  • Facebook
  • Linkedin
  • Twitter
  • https//www.coherentmarketinsights.com/
About PowerShow.com